Improvement in severity and symptoms of major depressive disorder with zuranolone assessed by MADRS: Results from the phase 3, multicenter, randomized, double-blind, placebo-controlled waterfall study

Authors
Category Primary study
ConferenceNeuropsychopharmacology
Year 2021
This article has no abstract
Epistemonikos ID: 9d904625800159f283f68abf0ffea8d1a8a5fbb3
First added on: Apr 30, 2026